GMI-1359
- Generic Name
- GMI-1359
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 4
- Registration Number
- NCT04197999
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 58
- Registration Number
- NCT02931214
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath